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Abstract
Introduction: The prognosis of patients hospitalized with acute heart failure (AHF) is poor and risk stratification
may help clinicians guide care. The objectives of the Acute Heart Failure Database (AHEAD) registry are to assess
patient characteristics, etiology, treatment and outcome of AHF.
Methods: The AHEAD main registry includes patients hospitalized for AHF in seven centers with a Catheterization
Laboratory Service in the Czech Republic. The data were collected from September 2006 to October 2009. The
inclusion criteria for the database adhere to the European guidelines for AHF (2005) and patients were
systematically classified according to the basic syndromes, type and etiology of AHF.
Results: Of 4,153 patients, 12.7% died during hospitalization. The median length of hospitalization was 7.1 days.
Mean age of patients was 71.5 ± 12.4 years; men were younger (68.6 ± 12.4 years) compared to women (75.5 ±
11.5 years) (P < 0.001). De-novo heart failure was seen in 58.3% of the patients. According to the classification of
heart failure syndromes, acute decompensated heart failure (ADHF) was reported in 55.3%, hypertensive AHF in
4.4%, pulmonary edema in 18.4%, cardiogenic shock in 14.7%, high output failure in 3.3%, and right heart failure in
3.8%. The mortality of cardiogenic shock was 62.7%, of right AHF 16.7%, of pulmonary edema 7.1%, of high output
HF 6.1%, whereas the mortality of hypertensive AHF or ADHF was < 2.5%. According to multivariate analyses, low
systolic blood pressure, low cholesterol level, hyponatremia, hyperkalemia, the use of inotropic agents and
norepinephrine were predictive parameters for in-hospital mortality in patients without cardiogenic shock. Severe
left ventricular dysfunction and renal insufficiency were predictive parameters for mortality in patients with
cardiogenic shock. Invasive ventilation and age over 70 years were the most important predictive factors for
mortality in both genders with or without cardiogenic shock.
Conclusions: The AHEAD Main registry provides up-to-date information on the etiology, treatment and hospital
outcomes of patients hospitalized with AHF. The results highlight the highest risk patients.
Keywords: acute heart failure, AHEAD, in-hospital mortality, prognosis
Background
Acute heart failure (AHF) is a major and rapidly grow-
ing problem responsible for several million hospitaliza-
tions worldwide [1,2]. Heart failure (HF) causes
considerable morbidity and mortality, and produces a
tremendous burden on health economics worldwide.
The European Society of Cardiology defines AHF as
the rapid onset of symptoms and signs secondary to
abnormal cardiac function [3]. The clinical classification
of patients with AHF continues to evolve, and reflects
ongoing changes in the understanding of the pathophy-
siology of the syndrome [3-5]. AHF outcomes remain
poor. Prevalence of in-hospital mortality as high as 10%
and prevalence of re-hospitalization >50% within 1 year
have been reported [6,7]. In the prospective cohort of
hospitalized patients with AHF (ADHERE), in-hospital
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vey (EHFS II) had an in-hospital mortality of 6.7% [1].
Despite the magnitude of the burden of AHF and the
intense interest in this dire problem, effective new thera-
pies capable of reducing the prevalence of early mortal-
ity or re-hospitalization have not been developed over
the past decade [7]. The etiology of AHF is mainly
ischemic heart disease (IHD) [9]. Invasive methods in
cardiology have significantly expanded in recent years.
The aim of this work is to describe a large population
of patients hospitalized for syndromes of AHF, their in-
patient therapy and mortality and to assess major risk
factors of adverse short term prognosis in terms of fre-
quently used invasive and therapeutic methods. The
patients with AHF were systematically sorted according
to AHF guidelines [3].
Materials and methods
Study populations
The Acute Heart Failure Database (AHEAD) registry con-
sists of two independent parts. The AHEAD main registry
includes consecutive patients in seven centers with a 24-
hour Catheterization Laboratory service and centralized
care for patients with acute coronary syndromes (ACS)
from a region of about three million inhabitants. The
AHEAD network also includes five regional hospitals with-
out a Catheterization Laboratory service. The present work
includes only patients from the AHEAD main registry.
The inclusion criteria for the database adhere to the
European guidelines for AHF. Hence, there must be the
signs and symptoms of HF, confirmed left-ventricular
dysfunction (systolic or diastolic) and/or positive
response to therapy [3]. The decision on inclusion in the
registry and filling the database were done by responsible
cardiologists. There was no exclusion criterion. Patients
were systematically classified according to the type of
AHF (de novo or acute decompensation of chronic heart
failure), etiology of AHF (acute coronary syndrome,
chronic coronary artery disease, valvular disease, arrhyth-
mia, hypertensive crisis, and so on) and six basic syn-
dromes of AHF defined according to ESC guidelines [3]:
1) acute decompensated heart failure (ADHF - with signs
and symptoms of AHF, which are mild and do not fulfill
criteria for cardiogenic shock, pulmonary edema or
hypertensive crisis); 2) hypertensive AHF (symptoms of
AHF are accompanied by high blood pressure on admis-
sion and relatively preserved left ventricular function
with a chest radiograph compatible with acute pulmonary
edema); 3) pulmonary edema (accompanied by severe
respiratory distress, with crackles over the lungs and
orthopnea with O2 saturation usually <90% prior treat-
ment); 4) cardiogenic shock (defined as evidence of tissue
hypoperfusion induced by heart failure after correction of
preload, mostly with systolic BP <90 mmHg ongoing for
at least 30 minutes); 5) high output failure (characterized
by high cardiac output, usually with high heart rate often
caused by arrhythmias, thyrotoxicosis crisis and anemia);
and 6) right heart failure (characterized by low output
syndrome with increased jugular venous pressure,
increased liver size and hypotension).
Atrial fibrillation was defined as arrhythmia at admis-
sion and it was not distinguished whether it was a type
of paroxysmal, persistent or permanent.
The AHEAD main registry included 4,153 patients
hospitalized at seven Cardiology Departments with
Catheterization Laboratory facilities in four cities. Data
were collected prospectively from September 2006 until
October 2009 using a database accessible via the Inter-
net website http://www.ahead.registry.cz, and were eval-
uated continuously (including in-hospital mortality).
T h el o n g - t e r mm o r t a l i t yw a sf o l l o w e du s i n gac e n t r a -
lized database of the Ministry of Health of the Czech
Republic and will be published separately. Written
informed consent was obtained from all subjects. The
study protocol complied with the Declaration of Hel-
sinki, and was approved by the local Ethics Committee
of the Faculty Hospital Brno (Brno, Czech Republic).
Statistical analysis
Statistical analyses were performed by the Institute of Bios-
tatistics and Analyses of Masaryk University (Brno, Czech
Republic). Standard summary statistics were used to
describe primary data, absolute and relative frequencies,
median, the 5
th to 95
th percentile range, arithmetic means
and standard deviation. The statistical significance of differ-
ences between groups of patients in continuous parameters
was tested using the Mann-Whitney U test. The Fisher
exact test and maximum likelihood c
2 test were applied for
the analyses of differences in some of the categories.
The relationship between hospital mortality and its
potential predictors was analyzed by univariate logistic
regression and described by odds ratios, their 95% confi-
dence intervals (CI) and corresponding statistical signifi-
cance. Multivariate logistic regression combining expert
selection of predictors with a forward stepwise selection
algorithm was used for the definition of the multivariate
model for in-hospital mortality.
A level of a = 0.05 was used as the boundary for sta-
tistical significance in all analyses. Due to the large sam-
ple size, all statistical results were interpreted with
respect to their clinical significance. Statistical analyses
were undertaken using the SPSS 18.0.3 statistical pack-
age (SPSS, Chicago, IL, USA).
Results
Baseline characteristics
Of 4,153 patients, 526 (12.7%) died during hospitaliza-
tion. The median length of hospitalization was 7.1 days
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Page 2 of 13(5.5 days for those patients who died and 9.7 days for
those who were discharged home) and was identical for
men and women.
The baseline characteristics according to the syn-
dromes of AHF of patients enrolled in the AHEAD reg-
i s t r ya r es h o w ni nT a b l e1 .T h ed i f f e r e n c ea m o n g
individual syndromes in patients with de-novo and acute
decompensation of chronic heart failure is shown in Fig-
ure 1. The baseline laboratory parameters are shown in
Table 2. At admission hyponatremia (<130 mmol/L) was
found in 5.0% of patients, hyperkalemia (>5.5 mmol/l)
in 3.9% of patients and anemia (<120 g/L women, 130
g/L men) in 35.1% of patients. Medications being taken
on admission and in surviving patients on discharge
from the hospital are shown in Table 3. When compar-
ing the medication of patients with pre-existing chronic
heart failure on admission and at discharge, we observed
a significant increase of ACEI (from 58.0% to 67.1%),
beta-blockers (from 64.1% to 78.2%), diuretics (from
76.0% to 94.9%), spironolactone (from 41.2% to 71.7%),
antiarrhytmics (from 17.5% to 22.0%) and digoxin (from
25.5% to 28.6%) during hospitalization.
Men were younger (68.6 ± 12.4 years) compared to
women (75.5 ± 11.5 years) (P < 0.001) and in-hospital mor-
tality was 13.0% for men and 12.2% for women (P = NS).
Hypertensive AHF was a more frequent etiology in women
than in men (8.5% versus 3.5%; P < 0.01). Men more fre-
quently had ACS (37.1% versus 33.3%; P =0 . 0 1 ) ,w o m e n
had more comorbidities such as chronic hypertension, dia-
betes mellitus, rhythm disturbances or stroke. Patients with
acute decompensation of chronic heart failure (N = 1,693,
42% of all patients) more frequently had comorbidities
such as hypertension, diabetes mellitus and atrial fibrilla-
tion and their in-hospital mortality was 11.3% while in-hos-
pital mortality of patients with de-novo HF was 14.0% (P <
0.05). Patients with acute coronary syndrome (ACS, N =
1,503, 36.2% of all patients) had lower in-hospital mortality
than those without ACS (9.7% versus 18.1%; P < 0.01) and
patients <70 years (N = 1,661, 40% of all patients) had
lower in-hospital mortality than older patients (10.1% ver-
sus 14.4%; P < 0.01). The highest in-hospital mortality was
in patients with cardiogenic shock and right acute heart
failure; the lowest in-hospital mortality was in patients with
hypertensive AHF (Figure 2). The most frequent etiologies
of AHF were ACS (36.2%), chronic coronary artery disease
(19.9%), valvular disease (10.4%), arrhythmias (7.9%) and
hypertensive crisis (5.7%). The differences in etiologies
between de-novo and acute decompensation of chronic
heart failure are shown in Figure 3.
Coronary angiography and percutaneous coronary
intervention in patients with AHF
At admission 29.5% of patients had coronary revascular-
ization by percutaneous coronary intervention or
coronary artery bypass grafting in their medical history.
During hospitalization coronary angiography was per-
formed in 45.5% of patients, more often in younger
patients <70 years old (69.8% versus 55.6%; P < 0.01)
and in men (50.6% versus 41.0%; P < 0.001). Coronary
angiography findings at the time of discharge were
known in 62.6% of hospitalized patients in total. There
were significant differences among syndromes of AHF
(acute decompensated heart failure - 64.7%, hypertensive
HF - 32.4%, pulmonary edema - 66.8%, cardiogenic
shock - 70%, AHF with high output - 28.8%, and right
AHF - 39.7%; P < 0.001). Percutaneous coronary inter-
vention was performed in 25.3% of patients, in 80.4% of
patients with AHF and myocardial infarction with ST
segment elevations, in 38.5% of patients with AHF and
myocardial infarction without ST elevations and in 4.9%
of patients without ACS.
During the course of hospitalization, noradrenaline was
used in 19.0%, adrenaline in 8.9%, dobutamine in 10.0%,
dopamine in 8.7% and levosimendan in 3.7% of patients.
The use of vasopressors and inotropes according to the
clinical syndromes is shown in detail in Table 4. Admin-
istration of adrenaline was associated with in-hospital
resuscitation (88.3%) and also with high in-hospital mor-
tality (84.4%). Adrenaline only was used in 15% of all
administrations; the most often combination was with
noradrenaline in 34.7%. Although vasopressors were also
administrated to patients with other syndromes then car-
diogenic shock, these patients did not meet the criteria
for cardiogenic shock according to the attending physi-
cians. They had either no signs of tissue hypoperfusion
and the treatment with vasopressors was only short-term
with low doses or vasopressors were administered for
another indication than cardiogenic shock, such as
hemorrhagic shock, septic shock, hypovolemia, and so
on. Hemodialysis was used in 2.4% of hospitalized
patients, intra-aortic balloon contrapulsation (IABC) was
used in 3.5% (N = 144) of all hospitalized patients
(according to syndromes: in cardiogenic shock in 79.9%
of patients; in pulmonary edema in 9.0% of patients; in
acute decompensated heart failure in 11.9%of patients;
according to etiology: in patients with ACS in 91.1%; in
patients with valvular disease in 4.9%; in patients with
chronic coronary artery disease in 4.0%). Pulmonary ven-
tilation was used in 25.0% (non-invasive ventilation in
11.1%, invasive ventilation in 16.1%). There were 94
patients who needed both invasive and non-invasive ven-
tilation mostly because of no clinical improvement after
non-invasive ventilation. The use of ventilator support
according to the clinical syndromes is shown in Table 5
and the in-hospital mortality according to the type of
ventilatory support used is shown in Table 6. Patients
who required invasive ventilation had higher hospital
mortality (13.9% versus 52.8%; P < 0.001) which was
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Page 3 of 13Table 1 Baseline characteristics of patients according to syndromes of acute heart failure.
Patients
characteristics
Total
1
(N = 4,153)
ADHF
(N = 2,241)
Hypertensive AHF (N =
179)
Pulmonary edema (N =
748)
Cardiogenic shock (N =
600)
AHF with high output (N
= 132)
Right AHF (N =
156)
P
2
Female 1,761 (42.4%) 905 (40.4%) 117 (65.4%) 330 (44.1%) 234 (39.0%) 70 (53.0%) 68 (43.6%) <0.001
Age 73.8 (49.3; 87.9) 73.8 (48.5; 87.6) 74.8 (49.3; 88.7) 73.8 (53.8; 88.3) 74.3 (50.3; 87.9) 76.2 (51.0; 91.1) 65.8 (35.3; 84.9) <0.001
>70 years 2,492 (60.0%) 1,342 (59.9%) 110 (61.5%) 468 (62.6%) 360 (60.0%) 93 (70.5%) 64 (41.0%) <0.001
De-novo HF 2,421 (58.3%) 1,179 (52.6%) 133 (74.3%) 437 (58.4%) 412 (68.7%) 84 (63.6%) 121 (77.6%) <0.001
ACS at admission 1,503 (36.2%) 742 (33.1%) 0 (0.0%) 305 (40.8%) 368 (61.3%) 10 (7.6%) 40 (25.6%) <0.001
NYHA III+IV 1,794 (43.2%) 1,094 (48.8%) 61 (34.0%) 323 (43.2%) 163 (27.2%) 49 (37.2%) 46 (29.5%) <0.001
Insignificant CAD 577 (13.9%) 354 (15.8%) 40 (22.3%) 93 (12.4%) 33 (5.5%) 18 (13.6%) 24 (15.4%) <0.001
Significant CAD 2,118 (51.0%) 1,154 (51.5%) 29 (16.2%) 411 (55.0%) 390 (65.0%) 27 (20.6%) 50 (32.1%) <0.001
CAD - unknown 1,458 (35.1%) 733 (32.7%) 110 (61.5%) 244 (32.6%) 177 (29.5%) 87 (65.8%) 82 (52.5%) <0.001
Chronic
hypertension
3,036 (73.1%) 1,578 (70.4%) 169 (94.3%) 604 (80.8%) 433 (72.1%) 90 (68.0%) 95 (60.7%) <0.001
Diabetes mellitus 1,769 (42.6%) 921 (41.1%) 77 (43.1%) 381 (51.0%) 264 (44.0%) 48 (36.2%) 38 (24.5%) <0.001
Previous MI 1,333 (32.1%) 708 (31.6%) 47 (26.4%) 275 (36.8%) 216 (36.0%) 31 (23.6%) 18 (11.3%) <0.001
Previous PCI or
CABG
1,225 (29.5%) 650 (29.0%) 6 (3.4%) 215 (28.7%) 271 (45.2%) 12 (9.1%) 39 (25.0%) <0.001
PM/ICD/CRT 507 (12.2%) 325 (14.5%) 15 (8.4%) 87 (11.6%) 45 (7.5%) 13 (9.8%) 10 (6.4%) <0.001
COPD 673 (16.2%) 374 (16.7%) 32 (17.8%) 123 (16.5%) 86 (14.4%) 27 (20.5%) 12 (8.0%) 0.027
Stroke or TIA in
history
685 (16.5%) 359 (16.0%) 47 (26.4%) 135 (18.0%) 94 (15.7%) 18 (13.4%) 15 (9.9%) 0.002
Atrial fibrillation 1,101 (26.5%) 634 (28.3%) 34 (19.0%) 160 (21.4%) 118 (19.7%) 97 (73.5%) 30 (19.2%) <0.001
Coronary
angiography
727 (17.5%) 441 (19.7%) 21 (11.7%) 138 (18.5%) 70 (11.6%) 16 (12.1%) 19 (12.3%) <0.001
Systolic BP 135 (80; 200) 136 (95; 195) 198 (140; 260) 145 (95; 218) 110 (55; 170) 140 (90; 180) 110 (60; 160) <0.001
Systolic BP ≤100 648 (15.6%) 224 (10.0%) 0 (0.0%) 65 (8.7%) 266 (44.4%) 20 (15.2%) 56 (36.1%) <0.001
Diastolic BP 80 (50; 110) 80 (60; 110) 100 (70; 150) 80 (60; 120) 65 (30; 95) 80 (58; 112) 70 (34; 100) <0.001
Heart rate 90 (54; 142) 85 (52; 140) 93 (55; 140) 98 (63; 141) 90 (45; 136) 130 (70; 170) 90 (49; 146) <0.001
Ejection fraction (%) 37 (16; 65) 36 (15; 65) 55 (30; 70) 35 (18; 60) 30 (12; 60) 52 (25; 70) 57 (25; 74) <0.001
Ejection fraction
≤30%
1,574 (37.9%) 858 (38.3%) 10 (5.6%) 320 (42.8%) 316 (52.6%) 13 (10.1%) 19 (12.2%) <0.001
1Syndromes are not known for 97 patients.
2Overall statistical significance of differences among syndromes is based on Kruskal-Wallis test for continuous variables and ML chi-square test for categorical variables.
ACS, acute coronary syndrome; ADHF, acute decompensated heart failure; BP, blood pressure; CABG, coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CRT,
cardiac resynchronisation therapy; ICD, implantable cardiac defibrillator; MI, myocardial infarction; PCI, percutaneous coronary intervention; PM, pacemaker; TIA, transient ischemic attack.
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3determined above all by heart failure severity. Patients
treated by non-invasive ventilation had milder forms of
acute heart failure (acute decompensated heart failure
41.0%; pulmonary edema 35.6%; and cardiogenic shock
13.0%) in comparison with patients treated by invasive
ventilation (acute decompensated heart failure 13.8%;
pulmonary edema 20.0%; and cardiogenic shock 58.6%).
We did not find significant differences in age, gender,
ejection fraction or comorbidities (hypertension, diabetes
mellitus, previous myocardial infarction, or chronic
obstructive pulmonary disease (COPD)) between the two
groups. Patients requiring invasive ventilation had slightly
higher levels of creatinine at admission (median 109 ver-
sus 126 μmol/L; P < 0.001).
Cardiogenic shock
In our study, 14.5% (N = 600) of patients were hospita-
lized with cardiogenic shock. In comparison with
patients without cardiogenic shock, we did not find sig-
nificant differences in age, gender, body mass index
(BMI), diabetes mellitus, hypertension or COPD. De-
novo acute heart failure was more frequent in patients
with cardiogenic shock (68.3% versus 55.2% in patients
without shock; P < 0.001) and acute coronary syndrome
was the most widespread etiology of shock (61.3% versus
31.1% in patients without shock; P < 0.001). Patients
with cardiogenic shock had higher blood glucose (10.8
mmol/L versus 7.7 mmol/L; P < 0.001), creatinine (129
μmol/L versus 107 μmol/L; P < 0.001) and lower blood
Figure 1 Syndromes according to acute decompensation of chronic heart failure and de-novo acute heart failure.A D C H F-A c u t e
decompensation of chronic heart failure, ADHF - Acute decompensated heart failure, AHF - Acute heart failure.
Table 2 Laboratory description of patients stratified according to gender
Patient characteristic Total (N = 4,153) Men (N = 2,397) Women (N = 1,756) P
2
Creatinine at admission (μmol/l) 109 (68; 241) 116 (75; 252) 100 (62; 220) <0.001
Creatinine max. (μmol/l) 125 (75; 353) 130 (81; 362) 117 (70; 333) <0.001
Na
+ (mmol/l) 139 (130; 144) 138 (130; 144) 139 (130; 145) 0.003
K
+ (mmol/l) 4.1 (3.2; 5.4) 4.2 (3.3; 5.4) 4.1 (3.1; 5.4) 0.002
Glycemia (mmol/l) 8.0 (4.8; 19.6) 7.8 (4.8; 18.5) 8.4 (4.9; 20.6) <0.001
Hemoglobin (g/l) 132 (96; 162) 137 (98; 165) 126 (94; 153) <0.001
NT-proBNP at entry
1 (pg/ml) 5,294 (285; 30 000) 5,873 (285; 30 000) 4,788 (329; 30 000) 0.378
BNP at entry
1 (pg/ml) 767 (38; 3 414) 750 (43; 3 712) 809 (18; 3 272) 0.911
Cholesterol (mmol/l) 4.4 (2.5; 6.8) 4.2 (2.4; 6.7) 4.6 (2.7; 7.0) <0.001
Uric acid (μmol/l) 413 (218; 691) 432 (224; 700) 385 (203; 672) <0.001
1Data available from fewer than 50% of patients.
2Statistical significance of differences between groups of patients is based on Mann-Whitney U.test. BNP, B-type
natriuretic peptide; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
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Page 5 of 13pressure (BP) on admission (110/65 mmHg versus 140/
80 mmHg; P < 0.001). Patients with shock needed more
intense treatment: adrenaline was used in 44.9%, nora-
drenaline in 73.6%, dobutamine in 36.1% and dopamine
in 25.0% of patients; 19.3% of patients received IABC
(Table 4).
Predictors of in-hospital mortality
The univariate and multivariate models of in-hospital
mortality predictors are shown in Table 7. Due to the
importance of cardiogenic shock for in-hospital mortal-
ity, the analysis was computed separately for patients
with and without cardiogenic shock. Pulmonary
Table 3 Pharmacotherapy of patients according to syndromes of acute heart failure.
Medication on
admission
1
Total
(N = 4,153)
ADHF
(N = 2,241)
Hypertensive
AHF (N = 179)
Pulmonary
edema
(N = 748)
Cardiogenic
shock (N = 600)
AHF with high
output (N = 132)
Right AHF
(N = 156)
P
3
Antiplatelets 1,865
(44.9%)
988 (44.1%) 84 (47.1%) 406 (54.3%) 259 (43.1%) 48 (36.0%) 35 (22.2%) <0.001
Anticoagulants 739 (17.8%) 459 (20.5%) 24 (13.4%) 99 (13.3%) 80 (13.3%) 26 (20.0%) 26 (16.7%) <0.001
ACE inhibitors 1,973
(47.5%)
1,069
(47.7%)
94 (52.3%) 383 (51.2%) 262 (43.6%) 55 (41.6%) 62 (39.6%) 0.016
AT2 511 (12.3%) 273 (12.2%) 28 (15.7%) 95 (12.7%) 62 (10.4%) 21 (16.0%) 18 (11.8%) 0.414
Beta-blockers 2,118
(51.0%)
1,185
(52.9%)
100 (55.8%) 399 (53.4%) 263 (43.8%) 58 (44.0%) 54 (34.7%) <0.001
Calcium
antagonists
968 (23.3%) 459 (20.5%) 54 (30.2%) 222 (29.7%) 147 (24.5%) 32 (24.0%) 37 (23.6%) <0.001
Diuretics 2,284
(55.0%)
1,307
(58.3%)
85 (47.7%) 408 (54.5%) 277 (46.2%) 70 (52.8%) 71 (45.8%) <0.001
Spironolactone 951 (22.9%) 594 (26.5%) 22 (12.2%) 153 (20.4%) 108 (18.0%) 21 (16.0%) 25 (16.0%) <0.001
Statins 1,325
(31.9%)
706 (31.5%) 53 (29.7%) 296 (39.6%) 172 (28.6%) 35 (26.4%) 28 (18.1%) <0.001
Other
antiarrhytmics
482 (11.6%) 289 (12.9%) 21 (11.6%) 78 (10.4%) 58 (9.6%) 18 (13.6%) 7 (4.2%) 0.005
Digoxin 702 (16.9%) 410 (18.3%) 32 (18.0%) 99 (13.3%) 93 (15.5%) 26 (20.0%) 19 (12.0%) 0.016
Nitrates 802 (19.3%) 412 (18.4%) 30 (16.9%) 188 (25.2%) 131 (21.9%) 19 (14.4%) 8 (4.9%) <0.001
2Medication at
discharge
Total
(N = 3,627)
ADHF
(N = 2,184)
Hypertensive
AHF (N = 175)
Pulmonary
edema
(N = 695)
Cardiogenic
shock (N = 224)
AHF with high
output (N = 124)
Right AHF
(N = 130)
Antiplatelets 2,441
(67.3%)
1,474
(67.5%)
122 (69.5%) 511 (73.5%) 159 (71.2%) 62 (50.0%) 48 (36.9%) <0.001
Anticoagulants 1,066
(29.4%)
612 (28.0%) 39 (22.4%) 170 (24.5%) 86 (38.5%) 53 (42.7%) 76 (58.5%) <0.001
ACE inhibitors 2,514
(69.3%)
1,570
(71.9%)
125 (71.3%) 499 (71.8%) 120 (53.5%) 72 (58.1%) 66 (50.8%) <0.001
AT2 370 (10.2%) 229 (10.5%) 33 (19.0%) 63 (9.1%) 9 (4.0%) 15 (12.1%) 11 (8.5%) <0.001
Beta-blockers 2,782
(76.7%)
1,743
(79.8%)
135 (77.0%) 531 (76.4%) 139 (61.9%) 92 (74.2%) 71 (54.6%) <0.001
Calcium
antagonists
638 (17.6%) 341 (15.6%) 89 (51.1%) 138 (19.9%) 12 (5.3%) 21 (16.9%) 21 (16.2%) <0.001
Diuretics 3,032
(83.6%)
1,850
(84.7%)
155 (88.5%) 626 (90.1%) 170 (75.7%) 95 (76.6%) 59 (45.4%) <0.001
Spironolactone 2,060
(56.8%)
1,321
(60.5%)
63 (36.2%) 444 (63.9%) 87 (38.9%) 53 (42.7%) 32 (24.6%) <0.001
Statins 2,093
(57.7%)
1,278
(58.5%)
86 (49.4%) 455 (65.5%) 119 (53.1%) 45 (36.3%) 54 (41.5%) <0.001
Other
antiarrhytmics
613 (16.9%) 360 (16.5%) 26 (14.9%) 112 (16.1%) 39 (17.3%) 52 (41.9%) 8 (6.2%) <0.001
Digoxin 707 (19.5%) 454 (20.8%) 24 (13.8%) 105 (15.1%) 36 (15.9%) 53 (42.7%) 13 (10.1%) <0.001
Nitrates 479 (13.2%) 317 (14.5%) 17 (9.8%) 106 (15.3%) 11 (4.9%) 11 (8.9%) 2 (1.5%) <0.001
1Syndromes are not known for 97 patients.
2Only patients surviving at discharge from hospital (N = 3627).
3Overall statistical significance of differences among
syndromes is based on ML chi-square test. ACE, angiotensin-converting enzyme; AT2, antagonist for type 2 receptor for angiotensin II; Other antiarrhytmics,
amiodarone, sotahexal, propafenone.
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meters for patients with and without cardiogenic shock.
Severe left ventricular systolic dysfunction and higher
creatinine at admission were independent predictors of
in-hospital mortality in patients with cardiogenic shock
while parameters such as low systolic blood pressure,
hyponatremia, low cholesterol and use of inotropes and
noradrenaline were negative prognostic parameters only
in patients without cardiogenic shock.
Discussion
The AHEAD main registry is one of the largest
national observational prospective databases of AHF.
The register was designed as multicenter and prospec-
tive with long-term mortality follow-up [10]. The data
are stored in a format that allows the creation of a sin-
gle aggregate dataset for research. The same data have
been collected for all patients, the characteristics of the
data were defined prior to its collection and the data
were collected in a systematic and prospective manner.
The completion of monitored data was 96%. The com-
parison of registries of AHF is difficult; therefore, we
tried to compare our results with some of them only
(ADHERE [8], ALARM-HF [11,12], EFICA [13], EHFS
I [14,15], EHFS II [1], FINN-AKVA [16], OPTIMIZE-
HF [9]). Table 8 demonstrates the basic characteristics
of recent comparable registries based on the classifica-
tions of The European Society of Cardiology (ESC)
guidelines on diagnosis and treatment of AHF 2005
[3].
Figure 2 In-hospital mortality according to syndromes of acute heart failure. Statistical significance denoted as ** <0.001; *<0.050. ADHF -
Acute decompensated heart failure, AHF - Acute heart failure.
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Our study population size is comparable with some of
the other registries [1,11]. The structure of the AHEAD
main registry is closest to the structure of EHFS II [1],
FIN-AKVA [16] and ALARM-HF [11]; the systematic
stratification of patients with AHF was based on the
guidelines of ESC [3] and the whole spectrum of
patients with AHF was covered. The average age of
patients with AHF is in the range of 69 to 75 years;
women hospitalized for AHF were significantly older
than the men. Patients with ACS comprise one third of
all patients. A higher percentage of patients with myo-
cardial infarction with ST elevation in the AHEAD main
registry was caused by enrollment of patients in specia-
lized cardiovascular centers with a higher frequency of
patients with ACS. The prevalence of underlying disease
in our study was comparable with that previously
reported: chronic hypertension (73.1% versus 54.7%
to72%), diabetes mellitus (42.6% versus 32.3% to 46.0%)
and atrial fibrillation (26.5% versus 25.0% to 31.0%)
[1,13,14,16]. Atrial fibrillation was present slightly more
often in patients with acute decompensation of chronic
heart failure (HF) (31.8%) than in de-novo HF (22.7%).
Generally, we could conclude that a typical man with
HF was younger with ACS whereas a typical woman
was older than 70 years of age with a non-ischemic
etiology of HF.
In-hospital mortality
The overall hospital mortality of 12.7% was comparable
with the mortality of ALARM-HF (11%) [11]. A lower
hospital mortality was reported in FINN-AKVA (7.1%)
[16], ADHERE (4.0%) [8,9], EHFS I (6.9%) [14,15], EHFS
II (6.7%) [1] and OPTIMIZE-HF (3.8%) [17]. The main
differences in mortality were based on different charac-
teristics of the study populations. Cardiogenic shock was
diagnosed in only 4% of the EHFS II population, in less
than 1% of the EHFS I population, in 2.3% of the FIN-
AKVA population, in 11.7% of the ALARM-HF popula-
tion and in 28.5% of the EFICA population. In our
study, 14.7% of the cases had cardiogenic shock. The
reported mortality for patients with cardiogenic shock
Figure 3 The differences in etiologies between de-novo and acute decompensation of chronic heart failure.A D C H F-A c u t e
decompensation of chronic heart failure, De-novo - Acute heart failure de-novo.
Table 4 Pharmacotherapy by vasopressors and inotropes according to the syndromes of acute heart failure.
Total
(N = 4,153)
ADHF
(N = 2,241)
Hypertensive
AHF (N = 179)
Pulmonary
edema (N = 748)
Cardiogenic
shock (N = 600)
AHF with high
output (N = 132)
Right AHF
(N = 156)
P
1
Noradrenaline 770 (19.0%) 132 (5.9%) 5 (2.8%) 128 (17.2%) 438 (73.6%) 11 (8.3%) 52 (33.5%) <0.001*
Adrenaline 360 (8.9%) 35 (1.6%) 1 (0.6%) 31 (4.2%) 268 (44.9%) 1 (0.8%) 21 (13.5%) <0.001*
Dobutamine 407 (10.0%) 95 (4.3%) 1 (0.6%) 77 (10.3%) 215 (36.1%) 4 (3.0%) 13 (8.4%) <0.001*
Dopamine 352 (8.7%) 108 (4.9%) 4 (2.2%) 51 (6.8%) 149 (25.0%) 8 (6.1%) 30 (19.4%) <0.001*
Levosimendan 148 (3.6%) 43 (1.9%) 1 (0.6%) 31 (4.2%) 69 (11.6%) - 3 (1.9%) <0.001*
1Overall statistical significance of differences among syndromes is based on ML chi-square test
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had cardiogenic shock), 43% in ALARM-HF, 39.6% in
EHFS II and 57.8% in EFICA. In our study, the in-hospi-
tal mortality of patients with cardiogenic shock was
62.7%. Lower mortality was seen in patients with de-
novo HF (58.8% versus 71.7%; P < 0.01) and in patients
under 70 years old (53.3% versus 68.9%; P <0 . 0 1 ) .T h e
higher number of patients with cardiogenic shock in the
AHEAD registry is determined by centralized care for
patients with ACS and severe forms of heart failure in
cardiovascular centers which were included in the
AHEAD main registry. The patient’s mortality is influ-
enced by the severity of heart failure which could be
expressed by the need for vasopressor administration.
For example, in EHFS II with a mortality of 39.6%, nora-
drenaline was administered in 24% of patients with
shock, while in the AHEAD registry (mortality 62.7%)
the administration of noradrenaline was required in 73%
of patients.
On the other hand, very low in-hospital mortality was
recorded in patients with hypertensive acute heart fail-
ure (2.2%) or in patients with acute decompensated
heart failure (2.5%). Patients enrolled in clinical trials
are usually younger, male, have fewer comorbidities, are
appropriately treated and have a better prognosis than
‘real life’ patients. Therefore, data from international
and/or national registries reflect more precisely the rea-
lity and can provide important information. The same
information can be found in the AHEAD main registry
(even though more men than women were included in
this registry).
Coronary angiography and percutaneous coronary
intervention in patients with AHF
A c u t ec o r o n a r ys y n d r o m ea n dc h r o n i ci s c h e m i ch e a r t
disease together accounted for 56.1% of the etiologies of
AHF in the AHEAD main registry. A total of 29.5% of
patients with AHF had percutaneous coronary interven-
tion (PCI) or coronary artery bypass grafting in their
medical history. Recent results of coronary angiography
were known in 17.5% of the admitted patients. Coronary
angiography was performed in 45.5% of the hospitalized
patients. At discharge coronary angiography findings
were known in 62.6% of the patients, more often in
patients with ACS (87.2% versus 47.1% in patients with-
out ACS). During hospitalization PCI was performed
mainly in patients with ACS; only 4.9% of patients with-
o u tA C Sw e r et r e a t e db yP C I .I nc o m p a r i s o n
Table 5 Use of ventilation support according to the clinical syndromes.
Total
(N = 4,153)
ADHF
(N = 2,241)
Hypertensive
AHF (N = 179)
Pulmonary
edema
(N = 748)
Cardiogenic
shock (N = 600)
AHF with high
output (N = 132)
Right AHF
(N = 156)
P
1
No ventilatory
support
3,116
(75.0%)
1,998
(89.2%)
143 (79.9%) 483 (64.6%) 160 (26.7%) 115 (87.1%) 121 (77.6%) <0.001*
Only NIV 368 (8.9%) 151 (6.7%) 24 (13.4%) 131 (17.5%) 48 (8.0%) 3 (2.3%) 11 (7.1%)
Only invasive
ventilation
575 (13.8%) 83 (3.7%) 10 (5.6%) 111 (14.8%) 333 (55.5%) 14 (10.6%) 23 (14.7%)
Both NIV and
invasive
ventilation
94 (2.3%) 9 (0.4%) 2 (1.1%) 23 (3.1%) 59 (9.8%) - 1 (0.6%)
1Overall statistical significance of differences among syndromes is based on ML chi-square test. ADHF - Acute decompensated heart failure, AHF - Acute heart
failure, NIV - non-invasive ventilation.
Table 6 Hospital mortality according to the ventilatory support used and syndromes of acute heart failure.
Total
(N = 4,153)
ADHF
(N = 2,241)
Hypertensive AHF
(N = 179)
Pulmonary
edema (N = 748)
Cardiogenic
shock (N = 600)
AHF with high
output (N = 132)
Right AHF
(N = 156)
Total N = 526
(12.7%)
N=5 7
(2.5%)
N = 4 (2.2%) N = 53 (7.1%) N = 376 (62.7%) N = 8 (6.1%) N = 26
(16.7%)
No ventilatory
support
122 (3.9%) 29 (1.5%) 1 (0.7%) 17 (3.5%) 64 (40.0%) 4 (3.5%) 5 (4.1%)
Only NIV 51 (13.9%) 2 (1.3%) 1 (4.2%) 12 (9.2%) 33 (68.8%) - 3 (27.3%)
Only invasive
ventilation
305 (53.0%) 24 (28.9%) 2 (20.0%) 19 (17.1%) 239 (71.8%) 4 (28.6%) 17 (73.9%)
NIV and invasive
ventilation
48 (51.1%) 2 (22.2%) - 5 (21.7%) 40 (67.8%) - 1 (100.0%)
P
1 <0.001* <0.001* 0.044* <0.001* <0.001* 0.012* <0.001*
1Statistical significance of differences in mortality among ventilaton categories is based on ML chi-square test.
Percentage in brackets indicates the number of deaths from the total number of patients with the clinical syndrome and ventilation mode from Table 5. ADHF -
Acute decompensated heart failure, AHF - Acute heart failure, NIV - Non-invasive ventilation.
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from EHFS II [1] and any revascularization (thromboly-
sis, PCI or CABG) was performed in 62% of the patients
with myocardial infarction with ST elevation in the
same study. The OPTIMIZE-HF registry evaluated
48,612 patients hospitalized for HF. In that registry cor-
onary artery disease (CAD) was strongly associated with
short- and long-term prognosis [17]. It is quite surpris-
ing that only 949 patients (<2%) underwent coronary
revascularization during the index hospitalization in this
survey.
Predictors of in-hospital mortality
We divided patients into those with cardiogenic shock
(N = 600) and very high mortality (62.7%) and those
without cardiogenic shock (N = 3,553) with low mortal-
ity rate (4.2%). That was similar to the ADHERE registry
[8,9] and even lower than in the ESHF II registry [1].
Using univariate logistic regression analyses we defined
all parameters that were related to in-hospital mortality.
Cardiopulmonary resuscitation and the use of adrenalin
were excluded from the models. Patients with cardio-
genic shock who were over 70 years old, with ejection
fraction (EF) <30%, with renal insufficiency and treated
with invasive pulmonary ventilation were at high risk of
mortality. Age over 70 years, low systolic blood pressure,
low cholesterol level, hyponatremia, hyperkalemia, the
use of any inotropic agents and norepinephrine and the
Table 7 The univariate and multivariate models of in hospital mortality predictors
With cardiogenic shock
(N = 600; in-hospital mortality = 62.7%)
Without cardiogenic shock
(N = 3,553; in-hospital mortality = 4.2%)
Univariate (crude) Multivariate adjusted Univariate (crude) Multivariate adjusted
Model parameter OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Age at hospital admission >70 years 1.9 (1.4-2.7) <0.001 2.0 (1.3-3.0) 0.001 1.8 (1.3-2.6) 0.001 2.7 (1.7-4.1) <0.001
BMI ≤28 (kg/m
2) 0.7 (0.5-1.0) 0.045 1.0 (0.7-1.4) 0.947
De-novo failure 0.6 (0.4-0.8) 0.004 1.3 (0.9-1.8) 0.167
Diabetes mellitus 1.4 (1.0-2.0) 0.035 1.2 (0.9-1.7) 0.286
DBP ≤60 (mmHg) 1.2 (0.9-1.7) 0.244 3.0 (2.1-4.3) <0.001
SBP ≤100 (mmHg) 1.0 (0.7-1.3) 0.710 3.6 (2.5-5.2) 0.000 1.6 (1.0-2.6) 0.050
Ejection fraction ≤30% 1.4 (1.0-2.0) 0.050 1.5 (1.0-2.2) 0.034 1.1 (0.8-1.7) 0.552
Atrial fibrillation/flutter 1.3 (0.8-1.9) 0.284 1.0 (0.7-1.5) 0.807
Haemoglobin ≤120 (g/l) 1.2 (0.8-1.7) 0.366 1.6 (1.1-2.3) 0.010
Na
+ ≤130 (mmol/l) 0.6 (0.3-1.0) 0.065 3.5 (2.1-5.9) <0.001 2.4 (1.3-4.7) 0.007
Cholesterol ≤3 (mmol/l) 1.0 (0.5-1.7) 0.891 2.5 (1.6-3.9) <0.001 2.4 (1.4-4.2) 0.002
K
+ >5.5 (mmol/l) 1.6 (0.8-3.1) 0.195 4.3 (2.5-7.6) <0.001 1.9 (1.0-3.9) 0.062
Creatinine at admission >120 (μmol/l) 1.4 (1.0-2.0) 0.030 1.5 (1.0-2.2) 0.048 1.8 (1.3-2.5) 0.001
Uric acid >500 (μmol/l) 1.2 (0.7-1.8) 0.542 1.3 (0.8-1.9) 0.299
Glycaemia >10 (mmol/l) 0.8 (0.6-1.1) 0.129 1.5 (1.1-2.1) 0.015
Invasive ventilation 2.8 (2.0-4.0) <0.001 2.9 (1.9-4.3) <0.001 15.3 (10.8-21.8) <0.001 5.5 (3.4-8.8) <0.001
Dobutamine, dopamine, levosimendan 0.8 (0.6-1.2) 0.269 5.9 (4.2-8.4) <0.001 1.7 (1.1-2.6) 0.030
Noradrenaline 1.7 (1.2-2.5) 0.003 13.9 (9.8-19.6) <0.001 3.9 (2.4-6.4) <0.001
BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; HR, heart rate; OR, odds ratio; SBP, systolic blood pressure.
Table 8 Comparison of basic characteristics of AHF
registries - AHEAD, ALARM-HF, EHFS II and FINN-AKVA.
AHEAD ALARM-
HF
EHFS II FINN-
AKVA
N 4,,153 4953 3,580 620
Age (mean) 71.5 66-70 69.9 75.1
Male (%) 57.6% 62.4% 61.3% 50.4
De-novo AHF 58.3% 36.2% 37.1% 49.0%
Syndromes of AHF
ADHF 55.3% 36.8% 65.4% 63.5%
Hypertensive AHF 4.4% 7.4% 11.4% 3.1%
Pulmonary edema 18.4% 36.7% 16.2% 26.3%
Cardiogenic shock 14.7% 11.7% 3.9% 2.3%
AHF with high output 3.3% 1.1% NA NA
Right AHF 3.8% 4.5% 3.2% 4.8%
Characteristics of population and hospital outcomes
ACS at admission 36.2% 36,8% 30.2% 31.9%
Chronic hypertension 73.1% 70.2% 62.5% 54.7%
Diabetes mellitus 43,0% 45.3% 32.8% 32.3%
Anaemia 35.1% 14.4% 14.7% NA
PCI during hospitalization 25.3% 12.8% 8.4% NA
EF LV < 30% 37.9% 26.0% 29.9% 16.2%
Hospital mortality 12.7% 12.0% 6.7% 7.1%
Follow-up Yes No 3 month Yes
NA - data were not evaluated or data are not available. ACS - Acute coronary
syndrome, ADHF - Acute decompensated heart failure, PCI - percutaneous
coronary intervention, EF LV - Ejection fraction of left ventricle.
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Page 10 of 13use of invasive pulmonary ventilation were independent
predictive parameters for in-hospital mortality in
patients without cardiogenic shock. In the OPTIMIZE
HF registry [17], the strongest predictor of mortality in
48,612 patients were low systolic BP, hyponatremia, high
levels of creatinine, and left-ventricular dysfunction [18].
Treatment
According to our results, there were only 64% of
patients who had been treated with beta-blockers and
58% of patients treated with ACEI in the group with
pre-existing knowledge of heart failure on admission.
These data are comparable with other registries (EHFS
II, FIN-AKVA, OPTIMIZE-HF). In comparison with
admission, at discharge there was a significant increase
in all classes of drugs indicated for the treatment of
heart failure (Table 3). The most common causes for
not recommending the optimal medication at discharge
were as follows: a tendency to hypotension at discharge,
at e n d e n c yt ob r a d y c a r d i aa td i s c h a r g eo ri n s t a b i l i t yo f
patients transferred to another department. Lack of the
optimal medication at discharge could be a cause of
recurrent acute decompensation but, at the same time,
intolerance of these drugs, particularly the tendency to
hypotension, is an adverse prognostic marker.
We found the total frequency of IABC use to be com-
parable with other registries (range of other registries
0.5% to 4.9%, AHEAD 3.5%) but the device was used
less in patients in cardiogenic shock (range 22% to 40%,
AHEAD 19.3%) [1,11,16,19,20]. The reason for less fre-
quent use is not clear as IABC is commonly available in
all hospitals with a Catheterization Laboratory without
any restrictions on use. The use of IABC is recom-
mended in the presence of hemodynamic impairment
when low coronary perfusion is suspected (particularly
with those in cardiogenic shock and with mechanical
complications during ACS).
Study limitations
The results presented here are only from hospitals with
a Catheterization Laboratory service (AHEAD main).
Results from regional hospitals participating in the
AHEAD network are not included. This could have led
to a higher contribution of patients with ACS and a
high percentage of patients who had undergone coron-
ary angiography and PCI during hospitalization. Despite
recommendations at the beginning of the study,
natriuretic peptides levels were determined in only half
of the patients.
Conclusion
The AHEAD main registry provides up-to-date informa-
tion on the demographic characteristics and the under-
lying conditions of AHF patients as well as the etiology,
investigation, treatment and prognosis of AHF in a
country with centralized care for ACS and with a high
percentage of patients who had received angiography
and coronary revascularization. The AHEAD registry
clearly demonstrates the gender differences of the
patients admitted with AHF: women were older with
higher SBP and more frequently preserved EF. The
prognosis of those with cardiogenic shock was poor; the
prognosis of patients with AHF without cardiogenic
shock was similar to that observed in other reports. We
defined the predictors of in-hospital mortality, since
these parameters should alert the physician to patients
at high risk of mortality.
Key Messages
￿ The most frequent etiologies of acute heart failure
in hospitalized patients were ACS (36.2%), chronic
ischemic heart disease (19.9%), valvular disease
(10.4%), arrhythmias (7.9%) and hypertensive crisis
(5.7%).
￿ The overall in-hospital mortality was 12.7%.
Patients with acute coronary syndrome had lower
mortality than those without ACS (9.7% versus
18.1%). The highest mortality was in the patients
with cardiogenic shock (62.7%) while there was a
very low mortality in patients with acute decompen-
sated heart failure (2.5%) and hypertensive acute
heart failure (2.2%).
￿ We found a frequent use of invasive methods: dur-
ing hospitalization coronary angiography was per-
formed in 45.5% of patients, percutaneous coronary
intervention in 25.3% and intra-aortic balloon con-
trapulsation was used in 19.3% of patients with car-
diogenic shock.
￿ Age >70 years, ejection fraction of left ventricle
≤30% and mild renal insufficiency with creatinine at
admission >120 μmol/l were adverse prognostic
parameters in patients with cardiogenic shock.
￿ Age >70 years, systolic blood pressure ≤100 mmHg
at admission, hyponatremia (Na
+ ≤130 mmol/l),
hypocholesterolemia (cholesterol ≤3 mmol/l), hyper-
kalemia (K
+ >5.5 mmol/l) and the use of invasive
ventilation, inotropes and vasopressors were adverse
prognostic parameters in patients without cardio-
genic shock.
List of abbreviation
ACE: angiotensin-converting enzyme; ACS: acute coron-
ary syndrome; ADHF: acute decompensated heart fail-
ure; AHEAD: Acute Heart Failure Database; AHF: acute
heart failure; AT2: antagonist for type 1 receptor for
angiotensin II; BNP: B-type natriuretic peptide; BP:
blood pressure; CABG: coronary artery bypass graft;
CAD: coronary artery disease; COPD: chronic
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Page 11 of 13obstructive pulmonary disease; CRT: cardiac resynchro-
nization therapy; DBP: diastolic blood pressure; EHFS II:
Second EuroHeart Failure Survey; IABC: intra-aortic
balloon contrapulsation; ICD: implantable cardiac defi-
brillator; IHD: ischemic heart disease; MI: myocardial
infarction; NIV: non-invasive ventilation; NT-proBNP:
N-terminal pro-B-type natriuretic peptide; PCI: percuta-
neous coronary intervention; PM: pacemaker; SBP: sys-
tolic blood pressure; TIA: transient ischemic attack.
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